Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Invested Capital: 2022-2025

Historic Invested Capital for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $340.7 million.

  • Entrada Therapeutics' Invested Capital fell 19.35% to $340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.7 million, marking a year-over-year decrease of 19.35%. This contributed to the annual value of $428.7 million for FY2024, which is 76.88% up from last year.
  • Per Entrada Therapeutics' latest filing, its Invested Capital stood at $340.7 million for Q3 2025, which was down 10.22% from $379.5 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Invested Capital peaked at $429.9 million during Q2 2024, and registered a low of $206.9 million during Q2 2023.
  • Moreover, its 3-year median value for Invested Capital was $340.7 million (2025), whereas its average is $328.5 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Invested Capital skyrocketed by 107.79% in 2024, and later dropped by 19.35% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Invested Capital (Quarterly) stood at $212.6 million in 2022, then rose by 14.02% to $242.4 million in 2023, then soared by 76.88% to $428.7 million in 2024, then fell by 19.35% to $340.7 million in 2025.
  • Its Invested Capital was $340.7 million in Q3 2025, compared to $379.5 million in Q2 2025 and $417.3 million in Q1 2025.